TBX1 and chordoma: It is expressed in almost all patients with chordoma, and chordoma-targeted tumor vaccines are developed based on this, including the Yeast-Brachyury (GI-6301) vaccine (16, 116), the MVA-Brachyury-TRICOM vaccine constructed using the modified vaccinia Ankara (MVA) carrier, and subsequent modified vaccines (117–119).